0000904454-24-000187.txt : 20240228 0000904454-24-000187.hdr.sgml : 20240228 20240228161748 ACCESSION NUMBER: 0000904454-24-000187 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240226 FILED AS OF DATE: 20240228 DATE AS OF CHANGE: 20240228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kapusta Matthew C CENTRAL INDEX KEY: 0001536290 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36294 FILM NUMBER: 24695655 MAIL ADDRESS: STREET 1: 7358 MCVAY ROAD CITY: GERMANTOWN STATE: TN ZIP: 38138 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: uniQure N.V. CENTRAL INDEX KEY: 0001590560 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: PAASHEUVELWEG 25A CITY: AMSTERDAM STATE: P7 ZIP: 1105 BP BUSINESS PHONE: 1-339-970-7000 MAIL ADDRESS: STREET 1: PAASHEUVELWEG 25A CITY: AMSTERDAM STATE: P7 ZIP: 1105 BP FORMER COMPANY: FORMER CONFORMED NAME: uniQure B.V. DATE OF NAME CHANGE: 20131030 4 1 edgar.xml PRIMARY DOCUMENT X0508 4 2024-02-26 0 0001590560 uniQure N.V. QURE 0001536290 Kapusta Matthew C C/O UNIQURE N.V. PAASHEUVELWEG 25A AMSTERDAM P7 11058BP NETHERLANDS 1 1 0 0 CEO, Managing Director 0 Ordinary Shares 2024-02-26 4 S 0 27904 6.35 D 440839 D As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.23 to $6.49. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Christian Klemt, Attorney-in-Fact 2024-02-28